Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Sitagliptin and metformin hydrochloride
Medication labelSitagliptin and metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic…
Why this: Advisory · dailymed-prescription
Sitagliptin and metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Sitagliptin and metformin hydrochloride extended-release tablets are not recommended in patients with type 1 diabetes mellitus. Sitagliptin and metformin hydrochloride extended-release tablets have not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using sitagliptin and metformin hydrochloride extended-release tablets [see Warnings and Precautions (5.2)].
- generic_name
- sitagliptin and metformin hydrochloride
- product_names
- sitagliptin and metformin hydrochloride
- ndc
- 70710-2036, 70710-2037, 70710-2038, 70710-2037-6, 70710-2036-6, 70710-2038-3
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en